Ultragenyx Pharmaceutical Inc. has recently been granted PRIME (Priority Medicines) designation by the European Medicines Agency (EMA) for its groundbreaking ...
As of January 19, 2024, the recent evaluations and projected prices for Ultragenyx Pharmaceutical (NASDAQ: RARE) showcase a diverse range ...
Vontobel Holding Ltd., a renowned financial institution, recently made headlines by reducing its holdings in Ultragenyx Pharmaceutical Inc. This move ...
On June 19, 2023, it was revealed that ETF Managers Group LLC had purchased a new position in shares of ...
